NO20031626D0 - Pyridonderivater for behandling av atherosklerose - Google Patents

Pyridonderivater for behandling av atherosklerose

Info

Publication number: NO20031626D0
Authority: NO; Norway
Prior art keywords: atherosclerosis; treatment; pyridone derivatives; pyridone; derivatives
Prior art date: 2000-10-10

Application number

NO20031626A

Other languages

English (en)

Other versions

NO20031626L (no

NO325107B1 (no

Inventor

Deirdre Mary Bernadette Hickey

Robert John Ife

Colin Andrew Leach

John Liddle

Ivan Leo Pinto

Stephen Allan Smith

Steven James Stanway

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-10

Filing date

2003-04-09

Publication date

2003-04-09

2003-04-09 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-04-09 Publication of NO20031626D0 publication Critical patent/NO20031626D0/no

2003-06-04 Publication of NO20031626L publication Critical patent/NO20031626L/no

2008-02-04 Publication of NO325107B1 publication Critical patent/NO325107B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Ceramic Engineering (AREA)
Manufacturing & Machinery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Materials Engineering (AREA)
Inorganic Chemistry (AREA)
Structural Engineering (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyridine Compounds (AREA)
Quinoline Compounds (AREA)

NO20031626A 2000-10-10 2003-04-09 Pyridonderivater, fremgangsmate for fremstilling av disse, farmasoytiske preparater omfattende slike, slike forbindelser til anvendelse i terapi og for fremstilling av medikamenter for behandling av atherosklerose NO325107B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0024808.8A GB0024808D0 (en)	2000-10-10	2000-10-10	Novel compounds
PCT/EP2001/011610 WO2002030904A1 (en)	2000-10-10	2001-10-05	Pyridinone derivatives for treatment of atherosclerosis

Publications (3)

Publication Number	Publication Date
NO20031626D0 true NO20031626D0 (no)	2003-04-09
NO20031626L NO20031626L (no)	2003-06-04
NO325107B1 NO325107B1 (no)	2008-02-04

Family

ID=9901006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031626A NO325107B1 (no)	2000-10-10	2003-04-09	Pyridonderivater, fremgangsmate for fremstilling av disse, farmasoytiske preparater omfattende slike, slike forbindelser til anvendelse i terapi og for fremstilling av medikamenter for behandling av atherosklerose

Country Status (28)

Country	Link
US (2)	US20040063753A1 (no)
EP (2)	EP1326841B1 (no)
JP (1)	JP4212354B2 (no)
KR (1)	KR100824134B1 (no)
CN (2)	CN1280275C (no)
AR (1)	AR035349A1 (no)
AT (1)	ATE538096T1 (no)
AU (2)	AU2002210524B2 (no)
BR (1)	BRPI0114576B1 (no)
CA (1)	CA2425268C (no)
CY (2)	CY1112442T1 (no)
CZ (1)	CZ304558B6 (no)
DK (2)	DK1326841T3 (no)
ES (2)	ES2399325T3 (no)
GB (1)	GB0024808D0 (no)
GC (1)	GC0000307A (no)
HU (1)	HU230767B1 (no)
IL (2)	IL155278A0 (no)
MX (1)	MXPA03003176A (no)
MY (1)	MY135766A (no)
NO (1)	NO325107B1 (no)
NZ (1)	NZ525225A (no)
PL (1)	PL207560B1 (no)
PT (2)	PT2258688E (no)
SI (2)	SI1326841T1 (no)
TW (1)	TWI293293B (no)
WO (1)	WO2002030904A1 (no)
ZA (1)	ZA200302785B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1686119T1 (sl) *	2000-02-16	2009-12-31	Smithkline Beecham Plc	Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
GB0119793D0 (en) *	2001-08-14	2001-10-03	Smithkline Beecham Plc	Novel compounds
GB0127139D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham	Novel compounds
GB0127140D0 (en) *	2001-11-10	2002-01-02	Smithkline Beecham	Novel compounds
GB0208279D0 (en) *	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
GB0208280D0 (en) *	2002-04-10	2002-05-22	Glaxo Group Ltd	Novel compounds
EP1735457A4 (en)	2004-04-16	2007-08-29	Glaxo Group Ltd	METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en)	2004-04-16	2015-01-15	Yaping Shou	Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
US20080090851A1 (en) *	2006-10-13	2008-04-17	Colin Andrew Leach	Bicyclic Heteroaromatic Compounds
US7705005B2 (en) *	2006-10-13	2010-04-27	Glaxo Group Limited	Bicyclic heteroaromatic compounds
US20080090852A1 (en) *	2006-10-13	2008-04-17	Colin Andrew Leach	Bicyclic Heteroaromatic Compounds
WO2008140449A1 (en)	2007-05-11	2008-11-20	Thomas Jefferson University	Methods of treatment and prevention of neurodegenerative diseases and disorders
US8962633B2 (en)	2007-05-11	2015-02-24	Thomas Jefferson University	Methods of treatment and prevention of metabolic bone diseases and disorders
EA018101B1 (ru) *	2007-05-11	2013-05-30	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Способы лечения кожных язв
US9512104B2 (en)	2009-07-28	2016-12-06	Auspex Pharmaceuticals, Inc.	Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en)	2009-07-28	2013-11-05	Auspex Pharmaceuticals, Inc	Quinolone inhibitors of lipoprotein-associated phospholipase A2
US20120220624A1 (en) *	2009-10-19	2012-08-30	Tony Siu	Pyrazolo [3,4-b] pyridin-4-one kinase inhibitors
WO2011160043A2 (en)	2010-06-18	2011-12-22	Whitehead Institute For Biomedical Research	Pla2g16 as a target for antiviral compounds
JP2013544854A (ja) *	2010-12-06	2013-12-19	グラクソグループリミテッド	化合物
MX2013006342A (es)	2010-12-06	2013-08-26	Glaxo Group Ltd	Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
WO2012080497A2 (en)	2010-12-17	2012-06-21	Glaxo Group Limited	Methods of treatment and prevention of eye diseases
WO2013000108A1 (zh) *	2011-06-27	2013-01-03	中国科学院上海药物研究所	唑类杂环化合物、其制备方法、药物组合物和用途
AU2012288865B2 (en)	2011-07-27	2015-10-01	Glaxo Group Limited	Bicyclic pyrimidone compounds
EP2739627A4 (en)	2011-07-27	2015-01-21	Glaxo Group Ltd	2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
CN103906744A (zh)	2011-09-01	2014-07-02	葛兰素集团有限公司	新晶型
UY35276A (es)	2013-01-25	2014-08-29	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos que inhiben la actividad de Lp-PLA2
CA2899124A1 (en)	2013-01-25	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Compounds
US20150344485A1 (en)	2013-01-25	2015-12-03	Glaxosmithkline Intellectual Property Development Limited	Bicyclic pyrimidone compounds as inhibitors of lp-pla2
EP2764866A1 (en)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Inhibitors of nedd8-activating enzyme
US20140283157A1 (en)	2013-03-15	2014-09-18	Diadexus, Inc.	Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012917A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en)	2014-07-22	2016-01-28	Glaxosmithkline Intellectual Property Development Limited	1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) *	2015-05-26	2018-02-16	河北东康生物科技有限公司	含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
AU2016275764B8 (en)	2015-06-11	2021-03-04	Basilea Pharmaceutica International AG	Efflux-pump inhibitors and therapeutic uses thereof
CN112574221B (zh) *	2019-09-30	2022-03-04	上海纽思克生物科技有限公司	四环嘧啶酮类化合物、其制备方法、其组合物和用途
CA3156783A1 (en)	2019-11-09	2021-05-14	Yun Jin	Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN112510260B (zh) *	2020-11-27	2022-11-04	珠海市赛纬电子材料股份有限公司	电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh)	2021-05-07	2022-11-08	上海赛默罗生物科技有限公司	嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5769527A (en)	1986-07-17	1998-06-23	Vari-Lite, Inc.	Computer controlled lighting system with distributed control resources
US5585246A (en)	1993-02-17	1996-12-17	Biometric Imaging, Inc.	Method for preparing a sample in a scan capillary for immunofluorescent interrogation
WO1995000649A1 (en)	1993-06-25	1995-01-05	Smithkline Beecham Plc	Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
DK0673426T3 (da)	1993-10-06	2001-08-27	Icos Corp	Blodpladeaktiveringsfaktor-acetylhydrolase
GB9421816D0 (en)	1994-10-29	1994-12-14	Smithkline Beecham Plc	Novel compounds
CZ192297A3 (en)	1994-12-22	1997-11-12	Smithkline Beecham Plc	Substituted azetidin-2-ones for treating atherosclerosis, process of their preparation and use
CH690264A5 (fr)	1995-06-30	2000-06-30	Symphar Sa	Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
BR9609445A (pt)	1995-07-01	1999-04-06	Smithkline Beecham Plc	Derivados de azetidinona no tratamento de aterosclerose
FR2743912B1 (fr)	1996-01-24	1998-04-10	Matra Communication	Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en)	1996-01-25	1997-11-04	Hazeltine Corporation	Validation of subscriber signals in a cellular radio network
GB9608649D0 (en)	1996-04-26	1996-07-03	Smithkline Beecham Plc	Novel compounds
CZ9902016A3 (cs) *	1996-12-05	1999-11-17	Amgen Inc.	Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití
GB9626616D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626615D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
GB9626536D0 (en)	1996-12-20	1997-02-05	Symphar Sa	Novel compounds
JP2001522844A (ja) *	1997-11-06	2001-11-20	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	ピリミジノン化合物およびそれを含有する医薬組成物
EP1105377B1 (en)	1998-08-21	2003-10-08	SmithKline Beecham plc	Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en)	1999-05-01	1999-06-30	Smithkline Beecham Plc	Novel compounds
DK1175408T3 (da)	1999-05-01	2005-04-11	Smithkline Beecham Plc	Pyrimidinonforbindelser
GB9910378D0 (en)	1999-05-05	1999-06-30	Smithkline Beecham Plc	Novel compounds

2000
- 2000-10-10 GB GBGB0024808.8A patent/GB0024808D0/en not_active Ceased
2001
- 2001-10-05 SI SI200131008T patent/SI1326841T1/sl unknown
- 2001-10-05 CZ CZ2003-1009A patent/CZ304558B6/cs not_active IP Right Cessation
- 2001-10-05 AU AU2002210524A patent/AU2002210524B2/en not_active Ceased
- 2001-10-05 DK DK01978400.8T patent/DK1326841T3/da active
- 2001-10-05 BR BRPI0114576A patent/BRPI0114576B1/pt not_active IP Right Cessation
- 2001-10-05 CN CNB018201253A patent/CN1280275C/zh not_active Expired - Fee Related
- 2001-10-05 IL IL15527801A patent/IL155278A0/xx unknown
- 2001-10-05 AT AT01978400T patent/ATE538096T1/de active
- 2001-10-05 PL PL366334A patent/PL207560B1/pl unknown
- 2001-10-05 ES ES10177773T patent/ES2399325T3/es not_active Expired - Lifetime
- 2001-10-05 PT PT101777738T patent/PT2258688E/pt unknown
- 2001-10-05 KR KR1020037005084A patent/KR100824134B1/ko not_active Expired - Fee Related
- 2001-10-05 CN CN200610128890XA patent/CN1951917B/zh not_active Expired - Fee Related
- 2001-10-05 MX MXPA03003176A patent/MXPA03003176A/es active IP Right Grant
- 2001-10-05 EP EP01978400A patent/EP1326841B1/en not_active Expired - Lifetime
- 2001-10-05 DK DK10177773.8T patent/DK2258688T3/da active
- 2001-10-05 WO PCT/EP2001/011610 patent/WO2002030904A1/en active IP Right Grant
- 2001-10-05 JP JP2002534290A patent/JP4212354B2/ja not_active Expired - Fee Related
- 2001-10-05 CA CA2425268A patent/CA2425268C/en not_active Expired - Fee Related
- 2001-10-05 EP EP10177773A patent/EP2258688B1/en not_active Expired - Lifetime
- 2001-10-05 AU AU1052402A patent/AU1052402A/xx active Pending
- 2001-10-05 PT PT01978400T patent/PT1326841E/pt unknown
- 2001-10-05 US US10/399,022 patent/US20040063753A1/en not_active Abandoned
- 2001-10-05 HU HU0302480A patent/HU230767B1/hu not_active IP Right Cessation
- 2001-10-05 ES ES01978400T patent/ES2378059T3/es not_active Expired - Lifetime
- 2001-10-05 SI SI200131019T patent/SI2258688T1/sl unknown
- 2001-10-05 NZ NZ525225A patent/NZ525225A/en not_active IP Right Cessation
- 2001-10-08 TW TW090124779A patent/TWI293293B/zh not_active IP Right Cessation
- 2001-10-08 MY MYPI20014669A patent/MY135766A/en unknown
- 2001-10-08 GC GCP20011661 patent/GC0000307A/en active
- 2001-10-10 AR ARP010104760A patent/AR035349A1/es active IP Right Grant
2003
- 2003-04-08 IL IL155278A patent/IL155278A/en not_active IP Right Cessation
- 2003-04-09 NO NO20031626A patent/NO325107B1/no not_active IP Right Cessation
- 2003-04-09 ZA ZA200302785A patent/ZA200302785B/en unknown
2004
- 2004-07-28 US US10/900,489 patent/US7235566B2/en not_active Expired - Lifetime
2012
- 2012-03-07 CY CY20121100228T patent/CY1112442T1/el unknown
2013
- 2013-02-08 CY CY20131100118T patent/CY1113648T1/el unknown

Also Published As

Publication number	Publication date
BRPI0114576B1 (pt)	2017-05-30
PT1326841E (pt)	2012-03-08
CY1113648T1 (el)	2016-06-22
CA2425268A1 (en)	2002-04-18
GC0000307A (en)	2006-11-01
US20040063753A1 (en)	2004-04-01
NO20031626L (no)	2003-06-04
CY1112442T1 (el)	2015-12-09
WO2002030904A1 (en)	2002-04-18
MY135766A (en)	2008-06-30
SI1326841T1 (sl)	2012-04-30
JP4212354B2 (ja)	2009-01-21
HK1058036A1 (en)	2004-04-30
BR0114576A (pt)	2004-07-27
HK1144941A1 (en)	2011-03-18
EP2258688A1 (en)	2010-12-08
PT2258688E (pt)	2013-02-04
CN1280275C (zh)	2006-10-18
IL155278A (en)	2015-05-31
PL207560B1 (pl)	2011-01-31
CN1951917B (zh)	2012-07-18
ES2399325T3 (es)	2013-03-27
NO325107B1 (no)	2008-02-04
AU1052402A (en)	2002-04-22
TWI293293B (en)	2008-02-11
HU230767B1 (hu)	2018-03-28
CA2425268C (en)	2011-09-13
EP1326841A1 (en)	2003-07-16
GB0024808D0 (en)	2000-11-22
ZA200302785B (en)	2004-07-09
ES2378059T3 (es)	2012-04-04
CN1479724A (zh)	2004-03-03
CZ20031009A3 (cs)	2003-11-12
DK1326841T3 (da)	2012-02-27
CZ304558B6 (cs)	2014-07-09
HUP0302480A3 (en)	2010-03-29
SI2258688T1 (sl)	2013-03-29
US20050014793A1 (en)	2005-01-20
HUP0302480A2 (hu)	2003-12-29
EP2258688B1 (en)	2012-11-21
CN1951917A (zh)	2007-04-25
KR100824134B1 (ko)	2008-04-21
PL366334A1 (en)	2005-01-24
AR035349A1 (es)	2004-05-12
AU2002210524B2 (en)	2004-06-03
MXPA03003176A (es)	2003-07-14
EP1326841B1 (en)	2011-12-21
US7235566B2 (en)	2007-06-26
NZ525225A (en)	2004-10-29
JP2004512283A (ja)	2004-04-22
DK2258688T3 (da)	2013-02-04
IL155278A0 (en)	2003-11-23
KR20030036916A (ko)	2003-05-09
ATE538096T1 (de)	2012-01-15

Publication	Publication Date	Title
NO20031626L (no)	2003-06-04	Pyridonderivater for behandling av atherosklerose
NO20013369D0 (no)	2001-07-06	Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
DK1343773T3 (da)	2007-02-05	Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
PT1343786E (pt)	2005-11-30	Novos derivados de pirazolopiridina substituidos por piridina
NO20013380D0 (no)	2001-07-06	2-aminobenzoksazinonderivater for behandling av fedme
CY2007029I2 (el)	2009-11-04	Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
MA26774A1 (fr)	2004-12-20	Derives de pyridinyl et de phenyl
NO20013381D0 (no)	2001-07-06	2-oksybenzoksazinonderivater for behandling av fedme
DK1448198T3 (da)	2008-01-07	Nicotin- eller isonicotin-benzothiazolderivater
NO20024775D0 (no)	2002-10-03	Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DK1226131T3 (da)	2004-04-19	Isoxazolcarboxamidderivater
NO20020622D0 (no)	2002-02-08	Polymorfer av torsemid
NO20024777L (no)	2002-12-03	Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
NO20024776D0 (no)	2002-10-03	Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
DE60104791D1 (de)	2004-09-16	Cyclobutendion-Derivate zur Behandlung von Artherosclerose
NO20030699L (no)	2003-04-10	Fremgangsmåte for fremstilling av cilostazol
NO20030515D0 (no)	2003-02-03	Fremgangsmåte for fremstilling av dinapsolin
DK1294694T3 (da)	2004-12-27	Fremgangsmåde til fremstilling af quinolinderivater
NO20030717D0 (no)	2003-02-14	Forbindelser for behandling av avhengighetsforstyrrelser
NO20024887D0 (no)	2002-10-10	Fremgangsmåte for fremstilling av benzokondenserte heterosykliske forbindelser
NO20023702L (no)	2002-08-06	Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20032297L (no)	2003-05-21	Fremgangsmåte for fremstilling av distamycinderivater
NO20020328D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20025385D0 (no)	2002-11-11	FremgangsmÕte for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20020327D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol

Legal Events

Date	Code	Title	Description
2020-05-25	MM1K	Lapsed by not paying the annual fees